Form 4 Filing: Zaki Mohamed - ADC Therapeutics SA

This filing reports the acquisition of 213,900 restricted stock units (RSUs) by Zaki Mohamed, Chief Medical Officer of ADC Therapeutics SA, on June 30, 2026. These RSUs, granted under an incentive award letter, will vest on the earlier of June 30, 2027, or termination of employment under specific conditions, subject to continued employment. Each RSU represents a contingent right to one common share. Following this award, Mr. Mohamed holds 896,317 shares. The transaction code "A" indicates an acquisition, and the price per share is reported as $0.00, as detailed in footnote F1.